Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Critical Limb Ischemia

Conditions

Critical Limb Ischemia

Trial Timeline

Feb 24, 2020 → Feb 4, 2022

NCT ID

NCT04306471

About Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.

Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. is a approved stage product being developed by Amgen for Critical Limb Ischemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04306471. Target conditions include Critical Limb Ischemia.

What happened to similar drugs?

3 of 8 similar drugs in Critical Limb Ischemia were approved

Approved (3) Terminated (2) Active (3)

✅DaptomycinMerckApproved

🔄Apixaban + ASA + Clopidogrel 75mgPfizerPhase 3

✅Colchicine (Colcrys®) + placebo + allopurinolRegeneron PharmaceuticalsApproved

🔄Rilonacept 80 mg + Rilonacept 160 mgRegeneron PharmaceuticalsPhase 3

❌Remodulin® (treprostinil sodium) InjectionUnited TherapeuticsPhase 3

❌Olimel (5.7%E / N9E)BaxterPhase 3

✅Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35EBaxterApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04306471	Approved	UNKNOWN	Feb 24, 2020	Feb 4, 2022	Critical Limb Ischemia

Competing Products

13 competing products in Critical Limb Ischemia

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Approved	43
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose	Merck	Phase 1	29
intensive insulin therapy to maintain normoglycemia	Novo Nordisk	Phase 2	35
Midazolam + Dexmedetomidine	Pfizer	Pre-clinical	26
Apixaban + ASA + Clopidogrel 75mg	Pfizer	Phase 3	36
Colchicine (Colcrys®) + placebo + allopurinol	Regeneron Pharmaceuticals	Approved	43
Rilonacept 80 mg + Rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	40
treprostinil dienthanolmine sustained release + Placebo	United Therapeutics	Phase 2	32
Remodulin® (treprostinil sodium) Injection	United Therapeutics	Phase 3	29
Olimel (5.7%E / N9E)	Baxter	Phase 3	29
Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E	Baxter	Approved	44
RJX + Placebo	ICON plc.	Phase 1	26
Ixmyelocel-T	Vericel	Phase 3	34